Roger S. McIntyre

MD | FRCPC

  • Professor of Psychiatry and Pharmacology, University of Toronto, Canada

  • Head of the Mood Disorders Psychopharmacology Unit at the University Health Network, Toronto, Canada

  • Chairman and Executive Director, Brain and Cognition Discovery Foundation (BCDF), Toronto, Canada

  • Director and Chair Scientific Advisory Board, Depression and Bipolar Support Alliance (DBSA), Chicago, Illinois, USA

  • Professor and Nanshan Scholar, Guangzhou Medical University, Guangzhou, China

  • Adjunct Professor College of Medicine, Korea University, Seoul, Republic of Korea

  • Visiting Professor, University of the Philippines, Manila, Philippines

  • Clinical Professor State University of New York (SUNY) Upstate Medical University, Syracuse, New York, USA

  • Clinical Professor Department of Psychiatry and Neurosciences University of California School of Medicine, Riverside, California, USA

Email | Twitter

Dr. Roger McIntyre is currently a Professor of Psychiatry and Pharmacology at the University of Toronto; Head of the Mood Disorders Psychopharmacology Unit at the University Health Network, Toronto, Canada; Executive Director of the Brain and Cognition Discovery Foundation in Toronto, Canada; Director as well as Co-Chair of the Scientific Advisory Board of the Depression and Bipolar Support Alliance (DBSA) from Chicago, Illinois, USA; Professor and Nanshan Scholar at Guangzhou Medical University; Adjunct Professor College of Medicine at Korea University; Clinical Professor State University of New York (SUNY) Upstate Medical University, Syracuse, New York, USA; Clinical Professor Department of Psychiatry and Neurosciences University of California School of Medicine, Riverside, California, USA; founder of the Canadian Rapid Treatment Centre of Excellence (CRTCE); and the CEO of Braxia Scientific Corp.

He was named by Clarivate Analytics in 2014, 2015, 2016, 2017, 2018, 2019, 2020, and 2021 as one of “The World’s Most Influential Scientific Minds”; this distinction is given by publishing the largest number of articles that rank among those most frequently cited by researchers globally in 21 broad fields of science and social science during the previous decade. Dr. McIntyre has also authored/co-authored more than 800 articles/manuscripts and has edited and/or co-edited several textbooks on mood disorders.

​Dr. McIntyre is involved in multiple research endeavors which primarily aim to characterize the phenomenology, neurobiology, and novel therapeutics of mood disorders, and has been especially interested in identifying innovative, rapid acting psychotropic treatments for mood disorders. His research has also extended into public health and implementation research at the population-based level.

​Dr. McIntyre is extensively involved in medical education.  He is a highly sought-after speaker at both national and international meetings, has received several teaching awards from the University of Toronto, Department of Psychiatry, and has been a recipient of the joint Canadian Psychiatric Association (CPA) / Council of Psychiatric Continuing Education Award for the Most Outstanding Continuing Education Activity in Psychiatry in Canada.

Dr. McIntyre has also contributed extensively to clinical practice guidelines; he is the lead author the Florida Best Practice Psychotherapeutic Medication Guidelines for Adults with Major Depressive Disorder and Bipolar Disorder, the lead author of the International Expert Opinion on the Available Evidence and Implementation of Ketamine and Esketamine in Mood Disorders, and a contributor to the CANMAT guidelines for the treatment of Depressive Disorders and Bipolar Disorders as well as the Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines for Mood Disorders. 

Dr. McIntyre completed his medical degree at Dalhousie University. He received his Psychiatry residency training and Fellowship in Psychiatric Pharmacology at the University of Toronto.